Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Annals of the Rheumatic Diseases

Volumn 77, Issue 2, 2018, Pages 165-174

  Kay, Jonathan ^a   Schoels, Monika M ^b   Dörner, Thomas ^c   Emery, Paul ^d   Kvien, Tore K ^e   Smolen, Josef S ^b   Breedveld, Ferdinand C ^f   Bijlsma, Johannes W J ^g   Braun, Jürgen ^g   Bykerk, Vivian P ^g   Danese, Silvio ^g   De Wit, Maarten P T ^g   Goncalves, João ^g   Huizinga, Tom W J ^g   Isaacs, John D ^g   Kavanaugh, Arthur F ^g   Kurki, Pekka ^g   Luger, Thomas A ^g   Müller Ladner, Ulf ^g   Pavelkam, Karel ^g   Schellekens, Huub ^g   Strangfeld, Anja ^g   Takeuchi, Tsutomu ^g   Voshaar, Marieke ^g   Weisman, Michael H ^g   more..

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e DIAKONHJEMMET HOSPITAL   (Norway)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Leiden University Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONSENSUS; DERMATOLOGY; DRUG COST; DRUG INDICATION; DRUG USE; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; HUMAN; IMMUNOGENICITY; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT; PHARMACOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RHEUMATIC DISEASE; RHEUMATOLOGY; SYSTEMATIC REVIEW (TOPIC); CONSENSUS DEVELOPMENT;

BIOSIMILAR PHARMACEUTICALS; CONSENSUS; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES;

EID: 85041496935     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211937     Document Type: Article

References (99)

1. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011;13:112.
2. Kay J, Feagan BG, Guirguis MS, et al. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals 2012;40:517-27.
3. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology - "O brave new world". Nat Rev Rheumatol 2012;8:430-6.
4. Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8.
5. Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 2015;11:713-24.
6. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82.
7. OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-based Medicine-Levels of Evidence (March 2009). 2009 http://www. cebm. net/ oxfordcentre-evidence-based-medicine-levels-evidence-march-2009/ (accessed 18 Jul 2017).
8. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH official website. 2017 http://www. ich. org/ (accessed 28 Jan 2017).
9. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. 2014 http://www. ema. europa. eu/ docs/ en-GB/ document- library/ Scientific- guideline/ 2014/ 10/ WC500176768. pdf (accessed 20 Nov 2016).
10. Biologics Price Competition and Innovation Act of 2009. United States Code. 111th Congress. 2nd Session edn. United States, 2010:804-21.
11. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. 2005 http://www. emea. europa. eu/ docs/ en- GB/ document- library/ Scientific- guideline/ 2009/ 09/ WC500003517. pdf (accessed 20 Nov 2016).
12. US Food & Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015 h ttp: //ww w.fd a.go v/do wnloads/ DrugsGuidanceComplianceRegul ator yInf ormation/ Guid ance s/ U CM291128. pdf (accessed 22 Jun 2016).
13. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 http://www. ema. europa. eu/ docs/ en-GB/ document-library/ Scientific- guideline/ 2015/ 01/ WC500180219. pdf (accessed 10 Nov 2016).
14. Gu N, Yi S, Kim TE, et al. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, singledose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 2011;33:2029-37.
15. Yi S, Kim SE, Park MK, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs 2012;26:177-84.
16. Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol 2015;11(Suppl 1):25-31.
17. Shin D, Kim Y, Kim YS, et al. A randomized, Phase I pharmacokinetic study comparing SB2 and Infliximab reference product (Remicade(®)) in healthy subjects. BioDrugs 2015;29:381-8.
18. Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis 2017;76:526-33.
19. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 2016;18:25.
20. von Richter O, Skerjanec A, Afonso M, et al. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol 2017;83:732-41.
21. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
22. Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2015;25:817-24.
23. Cohen S, Emery P, Greenwald M, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol 2016;82:129-38.
24. Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:566-70.
25. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93.
26. Rutherford AI, Galloway JB. Biosimilars in rheumatology: out of the laboratory and into practice. Expert Rev Clin Immunol 2016;12:697-9.
27. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis 2017;76:4-6.
28. World Health Organization Programme on International Nonproprietary Names (INN). Biological qualifier: An INN proposal. 2014 http://www. who. int/ medicines/ services/ inn/ bq-innproposal201407. pdf (accessed 18 Nov 2016).
29. US Food & Drug Administration. Guidance for industry: Nonproprietary naming of biological products. 2017 http ://w ww.f da.g ov/d ownl oads /Drugs/ GuidanceComplianceRegulato ryIn form ation/ Gui dances / UCM459987. pdf (accessed 27 Jan 2017).
30. Hoebert J, Laing R, Stephens P. The world medicines situation 2011: pharmaceutical consumption. Geneva, Switzerland: World Health Organization, 2011:1-17.
31. MacDougall D, Crowell K, Prager S, et al. IMS health white paper: biosimilars: who saves? 2016 https ://struct urecms-stag ing-psyclon e.netdn a-ssl. com/cl ient-assets/ dwonk /medi a/att achme nts/5 7dc/3 87d/ 6970 /2d6 c/ad 6f/0000/57 dc387d69702d6 cad6f0000. pdf? 1474050173 (accessed 25 Feb 2017).
32. Mulcahy AW, Predmore Z, Mattke S. The cost savings potential of biosimilar drugs in the United States. Perspectives. 2014 http://www. rand. org/ pubs/ perspectives/ PE127. html (accessed 18 Nov 2016).
33. Raedler LA, Zarxio RLA. Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States. Am Health Drug Benefits 2016;9:150-4.
34. Pfizer IncPfizer announces the U.S. availability of biosimilar INFLECTRA® (infliximabdyyb). Company to begin shipping to wholesalers in late November, 2016Pfizer Inc, 2016 New York, NY. http://www. pfizer. com/ news/ press-release/ press-releasedetail/ Pfizer-announces-the-u-s-availability- of- biosimilar-inflectra-infliximab-dyyb (accessed 7 Jan 2017).
35. Canadian Drug Expert Committee. CDEC final recommendation: Infliximab (Inflectra-Hospia Healthcare Corporation). Common Drug Review. 2014 https://www. cadth. ca/ media/ cdr/ complete/ cdr-complete-SE0384-Inflectra-Dec-23-14. pdf (accessed 7 Jan 2017).
36. Haustein R, et al. Saving money in the European healthcare systems with biosimilars. GaBI J 2012;1:120-6.
37. Mack A. Norway, biosimilars in different funding systems. What works? GaBI J 2015;4:90-2.
38. IMS Health. The impact of biosimilar competition. London, UK: IMS Health Inc., 2016:1-30.
39. Ruff L, Rezk MF, Uhlig T, et al. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in Europe. Value Health 2015;18:A639.
40. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
41. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
42. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
43. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
44. van Schouwenburg PA, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
45. Wang S-L, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodiesto-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013;78-79:39-44.
46. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
47. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. 2012 https://www. ema. europa. eu/ docs/ en-GB/ document-library/ Scientific-guideline/ 2012/ 06/ WC500128686. pdf (accessed 20 Nov 2016).
48. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267-81.
49. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 2016;65:1132-8.
50. Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis 2016;75:1693-6.
51. Gonçalves J, Araújo F, Cutolo M, et al. Biosimilar monoclonal antibodies: preclinical and clinical development aspects. Clin Exp Rheumatol 2016;34:698-705.
52. Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs 2017;9:365-83.
53. Cho IH, Lee N, Song D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs 2016;8:1136-55.
54. Hofmann HP, Kronthaler U, Fritsch C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)). Expert Opin Biol Ther 2016;16:1185-95.
55. Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs 2016;30:321-38.
56. Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs 2016;30:339-51.
57. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017;76:1679-87.
58. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:58-64.
59. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:51-7.
60. Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITYch study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 2017;176:928-38.
61. Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation's biosimilars program. N Engl J Med 2011;365:385-8.
62. US Food & Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. 2015 http ://w ww.f da.g ov/d ownl oads /drugs/ guidancecomplianceregulato ryin form ation/ gui dances / ucm444661. pdf (accessed 31 Oct 2016).
63. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006 http://www. ema. europa. eu/ docs/ en-GB/ document-library/Scientific-guideline/ 2009/ 09/ WC500003920. pdf (accessed 20 Nov 2016).
64. Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig 2013;105:37-43.
65. Danese S, Gomollon F. Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-9.
66. Gecse KB, Khanna R, van den Brink GR, et al. Biosimilars in IBD: hope or expectation? Gut 2013;62:803-7.
67. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014;8:1548-50.
68. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014;28:465-71.
69. Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014;13:751-5.
70. Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014;26:1-587.
71. Schreiber S, Luger T, Mittendorf T, et al. [Evolution of biologicals in inflammation medicine - biosimilars in gastroenterology, rheumatology and dermatology]. Dtsch Med Wochenschr 2014;139:2399-404.
72. Committee on Rheumatologic Care. American College of Rheumatology position statement: Biosimilars. 2016 http://www. rheumatology. org/ Portals/ 0/ Files/ Biosimilars-Position-Statement. pdf (accessed 20 Nov 2016).
73. Cohen SB, Genovese MC, Choy EH, et al. Randomized, double-blind, Phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis [abstract]. Arthritis Rheumatol 2015;67(suppl 10() http:// acrabstracts. org/ abstract/ randomized-double-blind-phase-3-study-of-efficacyand-safety-of-abp-501-compared-with-adalimumab-in-subjects-with-moderate-tosevere-rheumatoid-arthritis/.
74. Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017;76:1093-102.
75. Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 2015;15:1677-83.
76. Benucci M, Gobbi FL, Bandinelli F, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 2017;65:419-422.
77. Gentileschi S, Barreca C, Bellisai F, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.
78. Expert Opin Biol Ther 2016;16:1311-2.
79. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16.
80. Health Canada. Regulatory decision summary INFLECTRA. 2016 http://www. hc-sc. gc. ca/ dhp-mps/ prodpharma/ rds-sdr/ drug-med/ rds-sdr-infectra-184564-eng. php (accessed 29 Sep 2016).
81. Kay J, Wyand M, Chandrashekara S, et al. BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of a randomized, double-blind, active comparator study [abstract]. Arthritis Rheumatol 2014;66:3538.
82. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs. continuation of SB5 or reference adalimumab (Humira®) in patients with rheumatoid arthritis: Results of phase III study [abstract]. 2016 http:// acrabstracts. org/ abstract/ sustained-efficacy-and-comparable-safety-andimmunogenicity-after-transition-to-sb5-an-adalimumab-biosimilar-vs-continuationof-sb5-or-reference-adalimumab-humira-in-patients-with-rheumatoi/ (accessed 7 Jan 2017).
83. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54.
84. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
85. Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis 2017;76:1986-91.
86. Thimmaraju PK, Rakshambikai R, Farista R, et al. Legislations on biosimilar interchangeability in the US and EU-developments far from visibility. GaBI Online-Generics and Biosimilars Initiative 2015. 2015 http://www. gabionline. net/ Sponsored-Articles/ Legislations-on-biosimilar-interchangeability-in-the-US-and-EU-developmentsfar-from-visibility (accessed 20 Nov 2016).
87. Food US, Administration D. Guidance for industry: Considerations in demonstrating interchangeability with a reference product, draft guidance. 2017 http ://w ww.f da.g ov/d ownl oads /Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ UCM537135.p df? source=g ovdelive ry& utm-medium=email&u tm-source=g ovdelivery (accessed 17 Jan 2017).
88. Gómez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
89. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
90. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.
91. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
92. Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res 2012;64:1125-34.
93. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014;73:1673-6.
94. Mercer LK, Galloway JB, Lunt M, et al. BSRBR Control Centre Consortium. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2017;76:497-503.
95. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007;56:2135-42.
96. Fonseca JE, Gonçalves J, Araújo F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port 2014;39:60-71.
97. Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, et al. Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Reumatol Clin 2015;11:269-78.
98. Azevedo VF, Meirelles ES, Kochen JA, et al. Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease - Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmun Rev 2015;14:769-73.
99. British Society for Rheumatology. Position statement on biosimilar medicines (Revised January 2017). 2017 http://www. rheumatology. org. uk/ includes/ documents/cm-docs/ 2017/r/revised-bsr-biosimilars-position-statement-jan-2017.pdf (accessed14 Mar 2017).